Early trials demonstrate that the compound – a dual agonist of incretin and GIP receptors – presents a significant advance in body loss therapies. Beyond existing treatments , the peptide shows to affect food intake and metabolic expenditure by means of distinct routes. While more investigation is essential, current data generate excitement fo